Hemoglobin News and Research

RSS

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).

1 Jun 2011

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center.

1 Jun 2011

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study.

19 May 2011

Goat milk has nutritional characteristics beneficial to human health

Researchers at the University of Granada have found that goat milk has nutritional characteristics beneficial to health. They have determined that goat milk has many nutrients that make it similar to human milk.

19 May 2011

Mobile phones could help improve diabetes management in under-developed countries

A new study by the Veterans Affairs Ann Arbor Healthcare System and University of Michigan suggests that mobile phones could help low-income patients across the globe manage diabetes and other chronic diseases.

18 May 2011

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.

13 May 2011

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report.

10 May 2011

Structured exercise training can reduce HbA1c levels in patients with diabetes

Implementing structured exercise training, including aerobic, resistance or both, was associated with a greater reduction in hemoglobin A1c levels for patients with diabetes compared to patients in the control group, and longer weekly exercise duration was also associated with a greater decrease in these levels, according to results of an analysis of previous studies, published in the May 4 issue of JAMA.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

RBC transfusion linked to improved survival after intracerebral hemorrhage

In patients with intracerebral hemorrhage —a type of stroke caused by bleeding inside the brain—transfusion with red blood cells may improve the chances of survival, reports a study in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

3 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Low vitamin D levels linked to anemia in children

Pediatricians from Johns Hopkins Children's Center and elsewhere have discovered a link between low levels of vitamin D and anemia in children.

2 May 2011

Free medical clinic at Tacoma Dome to serve more patients

This Saturday's massive free medical clinic for the uninsured at the Tacoma Dome will add 250 more patient appointments as a result of an outpouring of support from medical and non-medical volunteers.

30 Apr 2011

New guide to help cancer patients manage symptoms, side effects

Cancer patients can be hit with a nasty array of symptoms and side effects, from anemia and anxiety to hair loss and hot flashes. Some of these problems can be so overwhelming that they cause patients to abandon life-saving treatments.

30 Apr 2011

Researchers unravel mechanism behind sickle hemoglobin protection against malaria

The latest issue of the journal Cell carries an article that is likely to help solve one of the long-standing mysteries of biomedicine. In a study that challenges currently held views, researchers at the Instituto Gulbenkian de Ci-ncia, in Portugal, unravel the molecular mechanism whereby sickle cell hemoglobin confers a survival advantage against malaria, the disease caused by Plasmodium infection.

29 Apr 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.